AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

In early corporate news, AstraZeneca receives EU approval for a bladder cancer therapy, and a subdued housing market leaves MJ Gleeson eyeing adjusted pretax profit at the lower end of current market ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

The biopharmaceutical giant AstraZeneca is considering moving their stock listing from the London Stock Exchange to the US in ...

Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

The British government and the pharmaceutical industry remain far apart in a dispute over drug pricing that has delayed publication of a long-pending plan for the UK life sciences sector.

In turn, while the overall impact from them is still yet to be seen, Mr Bailey says tightening rates further could be more ...

Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...